» Articles » PMID: 37900001

Therapeutic Potential Targeting Podocyte Mitochondrial Dysfunction in Focal Segmental Glomerulosclerosis

Overview
Specialty Nephrology
Date 2023 Oct 30
PMID 37900001
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Podocytes are essential components of the glomerular filtration barrier and essential for the proper filtration function of the glomerulus. Podocyte injury under various stress conditions is the primary pathogenesis and key determinant of focal segmental glomerulosclerosis (FSGS) with prominent clinical manifestations of proteinuria or nephrotic syndrome.

Summary: Under physiological conditions, a highly coordinated mitochondrial quality control system, including antioxidant defenses, mitochondrial dynamics (fusion, fission, and mitophagy), and mitochondrial biogenesis, guarantees the sophisticated structure and various functions of podocytes. However, under FSGS pathological conditions, mitochondria encounter oxidative stress, dynamics disturbances, and defective mitochondrial biogenesis. Moreover, mutations in mitochondrial DNA and mitochondria-related genes are also strongly associated with FSGS. Based on these pieces of evidence, bioactive agents that function to relieve mitochondrial oxidative stress and promote mitochondrial biogenesis have been proven effective in preclinical FSGS models. Targeting the mitochondrial network is expected to provide new therapeutic strategies for the treatment of FSGS and delay its progression to end-stage renal disease.

Key Messages: Mitochondrial dysfunction plays a key role in podocyte injury and FSGS progression. This review summarized recent advances in the study of mitochondrial homeostatic imbalance and dysfunction in FSGS and discussed the potential of mitochondria-targeted therapeutics in improving FSGS and retarding its progression to end-stage renal disease.

Citing Articles

Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury.

Zhu Y, Xu G Drug Des Devel Ther. 2025; 19:857-875.

PMID: 39935575 PMC: 11812565. DOI: 10.2147/DDDT.S498457.


Advances in Diagnosis and Treatment of Inherited Kidney Diseases in Children.

Wang G, Liao M, Tan D, Chen X, Chao R, Zhu Y Kidney Dis (Basel). 2024; 10(6):558-572.

PMID: 39664340 PMC: 11631113. DOI: 10.1159/000541564.


INF2 mutations cause kidney disease through a gain-of-function mechanism.

Subramanian B, Williams S, Karp S, Hennino M, Jacas S, Lee M Sci Adv. 2024; 10(46):eadr1017.

PMID: 39536114 PMC: 11559609. DOI: 10.1126/sciadv.adr1017.

References
1.
Widmeier E, Airik M, Hugo H, Schapiro D, Wedel J, Ghosh C . Treatment with 2,4-Dihydroxybenzoic Acid Prevents FSGS Progression and Renal Fibrosis in Podocyte-Specific Knockout Mice. J Am Soc Nephrol. 2019; 30(3):393-405. PMC: 6405149. DOI: 10.1681/ASN.2018060625. View

2.
Sidhom E, Kim C, Kost-Alimova M, Ting M, Keller K, Avila-Pacheco J . Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ-deficiency kidney disease. J Clin Invest. 2021; 131(5). PMC: 7919729. DOI: 10.1172/JCI141380. View

3.
Li L, Liu Y, Li S, Yang R, Zeng C, Rong W . Signal regulatory protein α protects podocytes through promoting autophagic activity. JCI Insight. 2019; 5. PMC: 6538339. DOI: 10.1172/jci.insight.124747. View

4.
OToole J . Renal manifestations of genetic mitochondrial disease. Int J Nephrol Renovasc Dis. 2014; 7:57-67. PMC: 3916636. DOI: 10.2147/IJNRD.S37887. View

5.
Hasegawa K, Sakamaki Y, Tamaki M, Wakino S . Nicotinamide mononucleotide ameliorates adriamycin-induced renal damage by epigenetically suppressing the NMN/NAD consumers mediated by Twist2. Sci Rep. 2022; 12(1):13712. PMC: 9374671. DOI: 10.1038/s41598-022-18147-2. View